News - Nephrology and Hepatology, Oncology


Popular Filters

Bayer CEO calls for greater appreciation of innovation

Bayer CEO calls for greater appreciation of innovation


Advances in cancer therapy are expected in the next years, thanks in particular to treatment using antibody-drug…

BayerNephrology and HepatologyOncologyPharmaceuticalResearchRespiratory and Pulmonary

US orphan status for Pharmalink’s Busulipo

US orphan status for Pharmalink’s Busulipo


Swedish specialty pharma group Pharmalink says its product Busulipo, (busulfan), a best-in-class conditioning…

BusulipoNefeconNephrology and HepatologyNorth AmericaOncologyPharmaceuticalPharmaLinkRegulationResearch

UK's NICE recommends new therapy for liver cancer patients


UK specialist health care company BTG (LSE: BTG) says that the UK's National Institute for Health and…

BiotechnologyBTGEuropeNephrology and HepatologyNordionOncologyRegulation

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

Amgen and KPCB to create Atara Biotherapeutics; Banner Pharmacaps changes hands


The world's largest biotech firm Amgen (Nasdaq: AMGN) and venture capital group Kleiner Perkins Caufield…

AmgenAtara BiotherapeuticsBanner PharmacapsBiotechnologyLicensingMergers & AcquisitionsNephrology and HepatologyOncologyPatheonPharmaceuticalProduction

AVEO and Astellas file NDA for tivozanib in kidney cancer


USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

Pfizer says Torisel combo fails in Ph III for kidney cancer


In a second research disappointment within a matter of days, US drugs behemoth Pfizer (NYSE: PFE) revealed…

AvastinNephrology and HepatologyOncologyPfizerPharmaceuticalResearchTorisel

Pfizer's Torisel fails in Ph III advanced renal cell cancer study


There was disappointment for global pharma behemoth Pfizer (NYSE: PFE) when it said that the Phase III…

BayerNephrology and HepatologyNexavarOncologyPfizerPharmaceuticalResearchTorisel

Affymax and Takeda get special Medicare code for Omontys


USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

AEterna Zentaris and Keryx shares tank as cancer drug flops in Ph III


Canadian drug developer AEterna Zentaris (TSX: AEZ) and US licensee Keryx Pharmaceutical (Nasdaq: KERX)…

AEterna ZentarisKeryx BiopharmaceuticalsLicensingNephrology and HepatologyOncologyperifosinePharmaceuticalResearchZerenex

BTG’s Voraxaze gains first approval, in USA


The US Food and Drug Administration has approved UK headquartered BTG International’s (LSE: BGC)…

BiotechnologyBTGNephrology and HepatologyNorth AmericaOncologyRegulationVoraxaze

Hospira progresses biosimilar Epogen


USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial


US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas…

Astellas PharmaAVEO PharmaceuticalsBayerBiotechnologyNephrology and HepatologyNexavarOncologyPharmaceuticalRegulationResearchtivozanib

Agenus out-licenses Russian rights to cancer vaccine


US biotech firm Agenus (Nasdaq: AGEN), known as Antigenics until January of this year, has entered into…

AgenusAntigenicsBiotechnologyChemRar Hi-TechEuropeLicensingNephrology and HepatologyNewVacOncologyOncophagePharmaceuticalResearch

Robust growth forecast for renal cell carcinoma market


The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the…

axitinibdovitinibGlaxoSmithKlineMarkets & MarketingNephrology and HepatologyNovartisOncologyPfizerPharmaceuticalSutentVotrient

FDA committee backs Affymax CKD drug


The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one,…

AffymaxNephrology and HepatologyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Back to top